0001062993-24-002322.txt : 20240207 0001062993-24-002322.hdr.sgml : 20240207 20240207173516 ACCESSION NUMBER: 0001062993-24-002322 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240207 DATE AS OF CHANGE: 20240207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41947 FILM NUMBER: 24606014 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER NAME: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc. CENTRAL INDEX KEY: 0001994702 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831365441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5106268331 MAIL ADDRESS: STREET 1: 5980 HORTON STREET STREET 2: SUITE 550 CITY: EMERYVILLE STATE: CA ZIP: 94608 3 1 form3.xml INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES X0206 3 2024-02-07 0 0001994702 Kyverna Therapeutics, Inc. KYTX 0000882095 GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 0 0 1 0 Series A-2 Convertible Preferred Stock Common Stock 1514083 D Series B Convertible Preferred Stock Common Stock 1702036 D The convertible preferred stock is convertible at any time, at the holder's election, on a one-for-one basis, and will convert automatically upon the issuer's consummation of an initial public offering. The preferred stock has no expiration date. Reflects a 1-for-4.5511 reverse stock split of the issuer's common stock, effected on January 30, 2024. Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson 2024-02-07